Search

In 2016, a multicenter double-blind placebo-controlled randomized clinical trial in parallel groups was completed in the Russian Federation to evaluate the efficacy of the liquid dosage form of Anaferon for children in the treatment of acute respiratory viral infections in children. The design and main results of the study are presented in the largest foreign database ClinicalTrials. gov of the National Library of Medicine of the USA. In November 2018, the collection of reports of the XIII Russian Scientific and Practical Conference with international participation “Health is the basis of human potential: problems and solutions” published the article of the Russian chemist N.N. Khromov-Borisov, where the author questions the reliability of the study of the liquid form of Anaferon for children. The presented article analyzes the legitimacy of the author’s claims. From the point of view of statistics, the analysis of N.N. Khromov-Borisov cannot be considered objective and correct, since it contains gross methodological errors.

Acute respiratory infections (ARI) are major causes of morbidity in children. Symptomatic treatment is insufficiently effective and requires additional drugs with etiotropic action. This multi-center double blind placebo-controlled randomized clinical study with superiority model design considers a liquid formulation of Anaferon for children.Methods. The study included 142 children from 1 month to 3 years 11 month 29 days old with ARI of the upper respiratory tract. They were randomized into Anaferon for children and Placebo groups (71 in each group) via interactive voice randomization system. The treatment period was 5 days, observation period – 14 days. The average duration of the symptoms and the severity of the respiratory disease were used as primary efficacy endpoints.Results. All 142 patients were randomized and included into ITT (Intention to treat) analysis. 140 patients (70 patients in each group) were included into PP-analysis. The patients in the Anaferon for children group had better results with average duration of ARI as compared to the Placebo group (87.7±31.5h vs. 103.3±19.4h; p =0.007). The authors marked efficacy of Anaferon for children in such parameters as disease severity (ITT-analysis: p=0.0004), total severity of disease symptoms (ITT-analysis: ANOVA: “Group” factor p=0.0004; “Day” factor pConclusion. Anaferon for children proved their efficiency and safety in young children with ARI.